Nivolumab and its use in the second-line treatment of metastatic urothelial cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Witjes AJ, Lebret T, Compérat EM et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol. 71(3), 462–475 (2017).
  MedlineGoogle Scholar
• 2 Meeks JJ, Bellmunt J, Bochner BH et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 62(3), 523–533 (2012).
  Medline CASGoogle Scholar
• 3 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J. Clin. 67(1), 7–30 (2017).
  MedlineGoogle Scholar
• 4 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer v5 (2017).
  Google Scholar
• 5 Kaufman D, Raghavan D, Carducci M et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. 18(9), 1921–1927 (2000).
  Medline CASGoogle Scholar
• 6 von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 3068–3077 (2000).
  Medline CASGoogle Scholar
• 7 Kamat AM, Hegarty PK, Gee JR et al. ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur. Urol. 63(1), 4–15 (2013).
  MedlineGoogle Scholar
• 8 Bellmunt J, von der Maase H, Mead GM et al. Randomized Phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J. Clin. Oncol. 30(10), 1107–1113 (2012).
  Medline CASGoogle Scholar
• 9 Loehrer SPJ, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10(7), 1066–1073 (1992).
  MedlineGoogle Scholar
• 10 Yafi FA, North S, Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr. Oncol. 18(1), e25–e34 (2011).
  Medline CASGoogle Scholar
• 11 Galsky MD, Pal SK, Chowdhury S et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 121(15), 2586–2593 (2015).
  Medline CASGoogle Scholar
• 12 Raggi D, Miceli R, Sonpavde G et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann. Oncol. 27(1), 49–61 (2016).
  Medline CASGoogle Scholar
• 13 Couzin-Fraenkel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 342(6165), 1432–1433 (2013).
  MedlineGoogle Scholar
• 14 Brester SF, Simons JW. Gene therapy in urological oncology: principles, strategies and potential. Eur. Urol. 25, 177–181 (1994).
  MedlineGoogle Scholar
• 15 Bellmunt J, Fougeray R, Rosenberg JE et al. Long-term survival results of a randomized Phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann. Oncol. 24(6), 1466–1472 (2013).
  Medline CASGoogle Scholar
• 16 Bellmunt J, Kerst JM, Vazquez F. A randomized Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Ann. Oncol. 28(7), 1517–1522 (2017).
  Medline CASGoogle Scholar
• 17 Patel MR, Elettron J, Infante JR et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohort of an open-label, Phase I trial. Lancet Oncol. 19(1), 51–64 (2018).
  Medline CASGoogle Scholar
• 18 Petrylak DP, de Wit R, Chi KN et al. Ramucirumab plus docetaxel versus placebo in patients with locally advanced or metastic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, Phase III study. Lancet 390(10109), 2266–2277 (2017).
  Medline CASGoogle Scholar
• 19 Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, Phase II trial. Lancet 387(10031), 1909–1920 (2016). •• Atezolizumab, an anti-PD-L1 antibody, was the first immune-checkpoint inhibitor to be approved by the US FDA in May 2016.
  Medline CASGoogle Scholar
• 20 Ko YJ, Canil CM, Mukherjee SD et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, Phase II study. Lancet Oncol. 14(8), 769–776 (2013).
  Medline CASGoogle Scholar
• 21 Powles T, O'Donnell PH, Massard C et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a Phase I/II open-label study. JAMA Oncol. 3(9), e172411 (2017).
  MedlineGoogle Scholar
• 22 Berman D, Korman A, Peck R et al. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. Pharmacol. Ther. 148, 132–153 (2015).
  Medline CASGoogle Scholar
• 23 Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20(19), 5064–5074 (2014). • Definition of the predictive role of PD-1 expression.
  Medline CASGoogle Scholar
• 24 Brahmer J, Tykodi S, Chow L et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
  Medline CASGoogle Scholar
• 25 Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small-cell lung cancer: a 5-year follow-up study. Tumori 98(6), 751–755 (2012).
  MedlineGoogle Scholar
• 26 Wang C, Thudium KB, Han M et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 2(9), 846–856 (2014).
  Medline CASGoogle Scholar
• 27 Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current challenges in cancer treatment. Clin. Ther. 38(7), 1551–1566 (2016).
  MedlineGoogle Scholar
• 28 Robertson AG, Kim J. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171(3), 540–556 (2017).
  Medline CASGoogle Scholar
• 29 Feng Y, Bajaj G, Wang X et al. Model-based analysis of nivolumab to support clinical pharmacology profiling in subjects with solid tumors [abstract]. Clin. Pharmacol. Ther. 97(Suppl. 1), S41–S42 (2015).
  Google Scholar
• 30 Bristol-Myers Squibb Company. Opdivo (nivolumab) injection, for intravenous use: US prescribing information (2015). www.fda.gov/.
  Google Scholar
• 31 European Medicines Agency. Opdivo 10 mg/ml concentrate for infusion: summary of product characteristics (2015). www.ema.europa.eu/.
  Google Scholar
• 32 Passey C, Simon J, Roy A et al. Assessment of drug interaction potential by nivolumab using cytokine modulation data [abstract no. 118]. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. New Orleans, LA, USA, March 2015.
  Google Scholar
• 33 Shih K, Arkenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 74(17), 1993–2013 (2014).
  Medline CASGoogle Scholar
• 34 Sharma P, Retz M, Siefker-Radtke A et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, Phase II trial. Lancet Oncol. 18(3), 312–322 (2017). •• This is the first published study with nivolumab in metastatic refractory urothelial carcinoma.
  Medline CASGoogle Scholar
• 35 Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14(8), 561–584 (2015).
  Medline CASGoogle Scholar
• 36 Apolo AB, Mortazavi A, Stein MNB et al. A Phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. J. Clin. Oncol. 35(Suppl. 6), 293 (2017). • Innovative combination Phase I study with cabozantinib and nivolumab +/- ipilimumab with promising data of overall response rate and survival.
  Google Scholar
• 37 Ribas A, Robert C, Hodi FS et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J. Clin. Oncol. 33(Suppl. 15), 3001 (2015).
  Google Scholar
• 38 Weinstein JN, Akbani R, Broom BM et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492), 315–322 (2014). • This is the first molecular characterization of bladder carcinoma from the The Cancer Genome Atlas.
  Medline CASGoogle Scholar
• 39 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012). •• Statement of immunotherapy regarding safety profile and efficacy.
  Medline CASGoogle Scholar
• 40 Sharma P, Callahan MK, Bono P et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, Phase I/II trial. Lancet Oncol. 17(11), 1590–1598 (2016).
  Medline CASGoogle Scholar
• 41 Sweis RF, Spranger S, Bao R et al. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol. Res. 4(7), 563–568 (2016).
  Medline CASGoogle Scholar
• 42 Galsky MD, Saci A, Szabo PM et al. Impact of tumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: exploratory analysis of the Phase II Checkmate 275 study. Ann. Oncol. 28(Suppl. 5), 1 (2017).
  Google Scholar
• 43 Routy B, Le Chatelier E, Derosa L et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371), 91–97 (2018).
  Medline CASGoogle Scholar
• 44 Tartari F, Santoni M, Burattini L et al. Economic sustainability of anti-PD-1 agents nivolumab and pembolizumab in cancer patients: recent insights and future challenges. Cancer Treat. 48, 20–40 (2016).
  Medline CASGoogle Scholar